P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS
A. Kulasekararaj,
R. Brodsky,
M. Griffin,
A. Kulagin,
M. Ogawa,
J. Wang,
A. Mujeebuddin,
J.-I. Nishimura,
R. Peffault de Latour,
J. Szer,
J. W. Lee
Affiliations
A. Kulasekararaj
1 King’s College Hospital, National Institute of Health Research/Wellcome King’s Clinical Research Facility and King’s College London, London, United Kingdom
R. Brodsky
2 Division of Hematology, Johns Hopkins Medicine, Baltimore, United States of America
M. Griffin
3 St James Hospital, NHS Teaching Hospitals, Leeds, United Kingdom
A. Kulagin
4 RM Gorbacheva Research Institute, Pavlov University, St Petersburg, Russia
M. Ogawa
5 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America
J. Wang
5 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America
A. Mujeebuddin
5 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America
J.-I. Nishimura
6 Osaka University Graduate School of Medicine, Suita, Japan
R. Peffault de Latour
7 Hôpital Saint-Louis AP-HP, Paris, France
J. Szer
8 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
J. W. Lee
9 Department of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
